Innovative immune system products
Opsona Therapeutics is developing innovative products to modulate the human immune system using a platform of small molecules, monoclonal antibodies and biologics.
These are all accepted and proven therapeutic approaches for acute and chronic inflammation & autoimmune diseases.
Opsona products in development include:
Clinical Development
- OPN-305 - Fully humanised antibody to reduce pro-inflammatory cytokine production associated with heart and kidney diseases. Read more about OPN-305
Preclinical Research
- Inflammasome - Small molecule programme to inhibit 1L-1 β production. Read more about Inflammasome
Partnering Opportunities
- OPN-501 - Colon Pro-drug Targeted platform technology, Oral prodrugs for the treatment of ulcerative colitis. Read more about OPN-501
- OpsoVac™ - novel TLR platform: Increased Efficacy and Antigen Sparing of Vaccines & Immunotherapeutics. Read more about OpsoVac™
Read more about collaboration and partnering opportunities